Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
5 min read
Aavocyte Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Aavocyte, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Evgen Pharma plc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Evgen Pharma plc, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Bellicum Pharmaceuticals, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Bellicum Pharmaceuticals, Inc, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Genfit SA Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Genfit SA, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Cogent Biosciences, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Cogent Biosciences, Inc, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Helixmith Co., Ltd Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Helixmith Co., Ltd, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
BioCryst Pharmaceuticals, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of BioCryst Pharmaceuticals, Inc, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Beijing Mabworks Biotech Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Beijing Mabworks Biotech, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Ascentage Pharma Group International Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Ascentage Pharma Group International, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Bavarian Nordic A/S Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Bavarian Nordic A/S, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Beijing SL Pharmaceutical Co., Ltd Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Beijing SL Pharmaceutical Co., Ltd, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Aligos Therapeutics, Inc Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
23 July 2026
A 2026 partnering scan of Aligos Therapeutics, Inc, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.